Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.63 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851337 | 0.91 | MAPK14 (0.52) | MAPK14BRAF | |
| SCHEMBL5897317 | 0.87 | MAPK14 (0.66) | MAPK14CSF1RRAF1BRAFCYP3A4 | |
| SCHEMBL2980968 | 0.83 | KCNQ3 (0.52) | MAPK14CSF1RBRAFLYN | |
| SCHEMBL7614087 | 0.83 | KCNQ3 (0.54) | MAPK14RAF1BRAF | |
| SCHEMBL5897069 | 0.82 | MAPK14 (0.60) | MAPK14RAF1BRAF | |
| SCHEMBL27501319 | 0.80 | MAPK14 (0.51) | MAPK14CSF1RRAF1BRAFLYN | |
| SCHEMBL5897136 | 0.78 | MAPK14 (0.75) | MAPK14RAF1BRAF | |
| SCHEMBL5897239 | 0.78 | MAPT (0.66) | MAPK14 | |
| SCHEMBL2302891 | 0.78 | MAPT (0.66) | RAF1BRAF | |
| SCHEMBL7850678 | 0.78 | MAPT (0.60) | MAPK14CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1142912-C | Amide derivs. useful as inhibitors of production of cytokines | — | 2004-03-24 | — | — | CN | claimed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
| CN-1321150-A | Amide derivs. useful as inhibitors of production of cytokines | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| CN-1142912-C | Amide derivs. useful as inhibitors of production of cytokines | — | 2004-03-24 | — | — | CN | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| CN-1321150-A | Amide derivs. useful as inhibitors of production of cytokines | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | MAPK14 2563/4885CSF1R 273/4885RAF1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.